Lexicon Pharmaceuticals (LXRX) Intangibles (2010 - 2020)

Lexicon Pharmaceuticals (LXRX) has 11 years of Intangibles data on file, last reported at $18.8 million in Q2 2020.

• Intangibles for Q2 2020 came in at $18.8 million, down 61.75% year-over-year; the trailing twelve-month figure through Jun 2020 was $18.8 million (down 61.75% YoY), and the FY2019 annual result was $19.7 million, down 60.66% from the prior year.
• Intangibles declined to $18.8 million in Q2 2020 per LXRX's latest filing, from $19.3 million in the prior quarter.
• Over five years, Intangibles peaked at $53.4 million in Q1 2016 and troughed at $18.8 million in Q2 2020.
• A 5-year average of $43.1 million and a median of $50.8 million in 2018 frame the typical range for Intangibles.
• The sharpest annual moves came in 2018 and 2020: Intangibles soared 108.28% in 2018, then sank 61.75% in 2020.
• A 5-year view of Intangibles shows it stood at $53.4 million in 2016, then fell by 2.76% to $51.9 million in 2017, then fell by 3.4% to $50.1 million in 2018, then tumbled by 60.66% to $19.7 million in 2019, then slipped by 4.48% to $18.8 million in 2020.
• Business Quant data shows LXRX's Intangibles at $18.8 million in Q2 2020, $19.3 million in Q1 2020, and $19.7 million in Q4 2019.